Portal Innovations CEO John Flavin predicts a robust 2026 for biotech, highlighting neurology, rare diseases, and obesity as key sectors. He expects a rebounding IPO market to fuel early-stage innovation in AI-enabled life sciences, CRISPR, and gene therapy. 4m 11s